Y Intercept Hong Kong Ltd Sells 65,965 Shares of Agios Pharmaceuticals, Inc. $AGIO

Y Intercept Hong Kong Ltd lessened its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 82.6% during the 1st quarter, Holdings Channel reports. The firm owned 13,866 shares of the biopharmaceutical company’s stock after selling 65,965 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Agios Pharmaceuticals were worth $469,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. AQR Capital Management LLC boosted its position in Agios Pharmaceuticals by 66.8% in the first quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company’s stock valued at $1,498,000 after buying an additional 20,625 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Agios Pharmaceuticals by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company’s stock worth $1,274,000 after buying an additional 2,920 shares in the last quarter. NewEdge Advisors LLC bought a new position in shares of Agios Pharmaceuticals in the first quarter valued at approximately $40,000. Goldman Sachs Group Inc. raised its stake in shares of Agios Pharmaceuticals by 16.1% in the first quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company’s stock valued at $19,299,000 after acquiring an additional 91,482 shares during the last quarter. Finally, Woodline Partners LP acquired a new position in shares of Agios Pharmaceuticals in the 1st quarter worth approximately $597,000.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on AGIO. Wall Street Zen raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, March 22nd. Royal Bank Of Canada boosted their price objective on Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. JPMorgan Chase & Co. decreased their target price on Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating on the stock in a report on Thursday, June 11th. HC Wainwright lowered their target price on Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Finally, Bank of America lifted their price target on Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. Six analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Agios Pharmaceuticals presently has an average rating of “Hold” and an average price target of $42.56.

Agios Pharmaceuticals Stock Performance

Shares of AGIO opened at $39.92 on Wednesday. The firm has a market capitalization of $2.37 billion, a price-to-earnings ratio of -5.51 and a beta of 0.54. The business’s fifty day moving average price is $32.30 and its two-hundred day moving average price is $30.10. Agios Pharmaceuticals, Inc. has a 52 week low of $22.24 and a 52 week high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) EPS for the quarter, beating the consensus estimate of ($1.81) by $0.12. The company had revenue of $20.75 million during the quarter, compared to analysts’ expectations of $13.30 million. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The firm’s revenue for the quarter was up 137.7% compared to the same quarter last year. As a group, research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.32 EPS for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.